Global practices of meningococcal vaccine use and impact on invasive disease

Hdl Handle:
http://hdl.handle.net/10144/322465
Title:
Global practices of meningococcal vaccine use and impact on invasive disease
Authors:
Ali, A; Jafri, R Z; Messonnier, N; Tevi-Benissan, C; Durrheim, D; Eskola, J; Fermon, F; Klugman, K P; Ramsay, M; Sow, S; Zhujun, S; Bhutta, Z; Abramson, J
Journal:
Pathogens and Global Health
Abstract:
A number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated meningococcal vaccines have lead to control of serogroup C meningococcal disease in the UK, Canada, Australia, Spain, Belgium, Ireland, and Iceland. Serogroup B disease, predominant in New Zealand, has been dramatically decreased, partly due to the introduction of an outer membrane vesicle (OMV) vaccine. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. The highest incidence region of the meningitis belt initiated vaccination with the serogroup A conjugate vaccine in 2010 and catch-up vaccination is ongoing. Overall results of this vaccine introduction are encouraging especially in countries with a moderate to high level of endemic disease. Continued surveillance is required to monitor effectiveness in countries that recently implemented these programs.
Publisher:
W.S. Maney & Son Ltd
Issue Date:
Jan-2014
URI:
http://hdl.handle.net/10144/322465
DOI:
10.1179/2047773214Y.0000000126
PubMed ID:
24548156
Language:
en
ISSN:
2047-7732
Appears in Collections:
Vaccination

Full metadata record

DC FieldValue Language
dc.contributor.authorAli, Aen_GB
dc.contributor.authorJafri, R Zen_GB
dc.contributor.authorMessonnier, Nen_GB
dc.contributor.authorTevi-Benissan, Cen_GB
dc.contributor.authorDurrheim, Den_GB
dc.contributor.authorEskola, Jen_GB
dc.contributor.authorFermon, Fen_GB
dc.contributor.authorKlugman, K Pen_GB
dc.contributor.authorRamsay, Men_GB
dc.contributor.authorSow, Sen_GB
dc.contributor.authorZhujun, Sen_GB
dc.contributor.authorBhutta, Zen_GB
dc.contributor.authorAbramson, Jen_GB
dc.date.accessioned2014-07-04T20:45:38Z-
dc.date.available2014-07-04T20:45:38Z-
dc.date.issued2014-01-
dc.identifier.citationGlobal practices of meningococcal vaccine use and impact on invasive disease. 2014, 108 (1):11-20 Pathog Glob Healthen_GB
dc.identifier.issn2047-7732-
dc.identifier.pmid24548156-
dc.identifier.doi10.1179/2047773214Y.0000000126-
dc.identifier.urihttp://hdl.handle.net/10144/322465-
dc.description.abstractA number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated meningococcal vaccines have lead to control of serogroup C meningococcal disease in the UK, Canada, Australia, Spain, Belgium, Ireland, and Iceland. Serogroup B disease, predominant in New Zealand, has been dramatically decreased, partly due to the introduction of an outer membrane vesicle (OMV) vaccine. Polysaccharide vaccines were used in high risk people in Saudi Arabia and Syria and in routine immunization in China and Egypt. The highest incidence region of the meningitis belt initiated vaccination with the serogroup A conjugate vaccine in 2010 and catch-up vaccination is ongoing. Overall results of this vaccine introduction are encouraging especially in countries with a moderate to high level of endemic disease. Continued surveillance is required to monitor effectiveness in countries that recently implemented these programs.en_GB
dc.language.isoenen
dc.publisherW.S. Maney & Son Ltden_GB
dc.rightsArchived with thanks to Pathogens and Global Healthen_GB
dc.subjectMeningitisen_GB
dc.subjectVaccinationen_GB
dc.titleGlobal practices of meningococcal vaccine use and impact on invasive diseaseen
dc.identifier.journalPathogens and Global Healthen_GB

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.